Date: 2017-05-16
Type of information: Company acquisition
Acquired company: HansaBioMed Life Sciences (Estonia)
Acquiring company: Lonza (Switzerland)
Amount: undisclosed
Terms:
- • On May 16,2017, Lonza announced the acquisition of HansaBioMed Life Sciences, a start-up company dedicated to the research and development, manufacturing, and distribution of products for the exosomes research market. As a new part of Lonza, HBM-LS will continue its product portfolio expansion of research products and support the development of cGMP-compliant exosome manufacturing processes. Lonza’s investment in Exosomics will help to support the continued research, development and pre-commercialization of non-invasive, exosome-based liquid biopsy cancer-screening tests.
Details:
- Exosomes are nano-sized vesicles released by all living cells in a finely regulated manner. Functioning as nano-bullets with multiple surface receptors for crossing biological barriers, tissue targeting and delivery of bioactive molecules, they have the potential of being developed for various applications in life sciences. Their acknowledged role as effectors in tissue regeneration, immune response and inflammation shows their potential as the next generation of vaccine development, drug delivery and off-the-shelf, cell-free regenerative therapies.
- Exosomes may play an important role in the field of liquid biopsies. They couldalso become the next generation of cell-free therapies in regenerative medicine.
Related: Technology - Services
Is general: Yes
